5 Simple Techniques For pentobarbital sodium over the counter
5 Simple Techniques For pentobarbital sodium over the counter
Blog Article
pentobarbital will decrease the extent or effect of buprenorphine buccal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital boosts effects of ifosfamide by influencing hepatic enzyme CYP2B6 metabolism. Use Warning/Monitor. Coadministration of ifosfamide with CYP2B6 inducers could enhance metabolism of ifosfamide to its metabolite. Monitor for enhanced effects/toxicities if put together with CYP2B6 inducers.
pentobarbital will lower the level or impact of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unknown.
Reserve concomitant prescribing of these drugs in people for whom other procedure solutions are insufficient. Restrict dosages and durations for the minimum required. Observe intently for indications of respiratory depression and sedation.
pentobarbital will decrease the extent or outcome of vinblastine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.
Comment: Barbiturates may possibly raise adverse effects, including respiratory despair, made by poisonous doses of TCAs. With therapeutic doses of TCAs, barbiturates raise metabolism and reduce blood concentrations of TCAs.
pentobarbital will lessen the level or influence of pimozide by website impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Mysterious.
pentobarbital improves toxicity of methoxyflurane by expanding metabolism. Contraindicated. Amplified metabolism of methoxyflurane to nephrotoxic compounds.
pentobarbital will lower the extent or influence of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will lower the extent or outcome of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will lessen the extent or effect of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Strong or moderate CYP3A inducers could decrease cobimetinib systemic exposure by >80% and minimize its efficacy.
Comment: Barbiturates may raise adverse effects, like respiratory depression, made by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates raise metabolism and decrease blood concentrations of TCAs.
pentobarbital will minimize the extent or outcome of parecoxib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.
pentobarbital will lessen the extent or effect of ramelteon by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unknown.